Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07727668 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: Iberdomide
PROCEDURE: CAR-T Leukapheresis
PROCEDURE: CAR-T Infusion

Sponsor

Shambavi Richard

Collaborators

[object Object]